174 related articles for article (PubMed ID: 9387206)
1. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
Landolfi R; Marchioli R
Semin Thromb Hemost; 1997; 23(5):473-8. PubMed ID: 9387206
[TBL] [Abstract][Full Text] [Related]
2. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
Finazzi G;
Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of low-dose aspirin in polycythemia vera.
Landolfi R; Marchioli R; Kutti J; Gisslinger H; Tognoni G; Patrono C; Barbui T;
N Engl J Med; 2004 Jan; 350(2):114-24. PubMed ID: 14711910
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and prevention of vascular complications in polycythemia vera.
Barbui T; Finazzi G
Semin Thromb Hemost; 1997; 23(5):455-61. PubMed ID: 9387204
[TBL] [Abstract][Full Text] [Related]
5. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
6. Treatment of polycythemia vera.
Barbui T; Finazzi G
Haematologica; 1998 Feb; 83(2):143-9. PubMed ID: 9549926
[TBL] [Abstract][Full Text] [Related]
7. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
Landolfi R; Patrono C
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():83-6. PubMed ID: 8951777
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
Finazzi G
Semin Thromb Hemost; 2006 Apr; 32(3):276-82. PubMed ID: 16673282
[TBL] [Abstract][Full Text] [Related]
9. The haematocrit and platelet target in polycythemia vera.
Di Nisio M; Barbui T; Di Gennaro L; Borrelli G; Finazzi G; Landolfi R; Leone G; Marfisi R; Porreca E; Ruggeri M; Rutjes AW; Tognoni G; Vannucchi AM; Marchioli R;
Br J Haematol; 2007 Jan; 136(2):249-59. PubMed ID: 17156406
[TBL] [Abstract][Full Text] [Related]
10. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
11. Front-line therapy in polycythemia vera and essential thrombocythemia.
Barbui T; Finazzi MC; Finazzi G
Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
[TBL] [Abstract][Full Text] [Related]
12. Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP).
Br J Haematol; 1997 May; 97(2):453-6. PubMed ID: 9163613
[TBL] [Abstract][Full Text] [Related]
13. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
Marchioli R; Finazzi G; Landolfi R; Kutti J; Gisslinger H; Patrono C; Marilus R; Villegas A; Tognoni G; Barbui T
J Clin Oncol; 2005 Apr; 23(10):2224-32. PubMed ID: 15710945
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs.
Crisà E; Venturino E; Passera R; Prina M; Schinco P; Borchiellini A; Giai V; Ciocca Vasino MA; Bazzan M; Vaccarino A; Boccadoro M; Ferrero D
Ann Hematol; 2010 Jul; 89(7):691-9. PubMed ID: 20146064
[TBL] [Abstract][Full Text] [Related]
15. Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients.
Bachleitner-Hofmann T; Grumbeck E; Gisslinger H
Thromb Res; 2003; 112(4):229-32. PubMed ID: 14987916
[TBL] [Abstract][Full Text] [Related]
16. Erythromelalgia and vascular complications in polycythemia vera.
Michiels JJ
Semin Thromb Hemost; 1997; 23(5):441-54. PubMed ID: 9387203
[TBL] [Abstract][Full Text] [Related]
17. Aspirin in essential thrombocythemia: status quo and quo vadis.
Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.
Second Chinese Cardiac Study (CCS-2) Collaborative Group
J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin.
Myers TJ; Steinberg WM; Rickles FR
Arch Intern Med; 1979 Jun; 139(6):695-8. PubMed ID: 443976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]